Ernexa Therapeutics (ERNA) risk factors, FY2024 10-K

Risks Related to our Business and Industry

1. 01We will require substantial additional capital to fund our operations and execute our business strategy, and we may not be able to raise adequate capital on a timely basis, on favorable terms, or at all
2. 02Unstable and unfavorable market and economic conditions may harm our ability to raise additional capital
3. 03We have incurred significant losses since our inception and expect to continue to incur losses for the foreseeable future, which, together with our limited financial resources and substantial capital requirements, make it difficult to assess our prospects
4. 04We depend substantially, and expect in the future to continue to depend, on in-licensed intellectual property. Such licenses impose obligations on our business, and if we fail to comply with those obligations, we could lose license rights, which would substantially harm our business
5. 05Our intellectual property rights may not adequately protect our business
6. 06We rely heavily on in-licensed intellectual property from Factor Limited. Loss of this license or termination of the Factor L&C Agreement could significantly harm our product development and ability to enter co-development strategic partnerships, materially impacting our business
7. 07We or our licensors may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license now or in the future
8. 08Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security
9. 09If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
10. 10Competition for skilled personnel in our industry is intense and competition for experienced scientists may limit our ability to hire and retain highly qualified personnel on acceptable terms. Despite our efforts to retain valuable employees, our employees may terminate their employment with us on short notice

Risks Related to New, Cutting Edge Technologies

1. 11Our product development relies on novel, inherently risky technologies. Synthetic mesenchymal stem cell therapy is a relatively new field, and our efforts may not result in effective treatments for human diseases
2. 12We are in an industry with intense competition and rapid technological change and our competitors may develop therapies that are more advanced, safer, or more effective than any therapy we develop in the future, which may adversely affect our financial condition
3. 13Negative public opinion and increased regulatory scrutiny due to ethical and other concerns surrounding the use of stem cell therapy or human tissue may damage public perception of our synthetic allogeneic iMSC product candidates or adversely affect our ability to conduct our business
4. 14The manufacture of biotechnology products is complex, and manufacturers often encounter difficulties in production

Risks Related to Ownership of our Common Stock

1. 15Seven stockholders collectively own a significant percentage of our outstanding common stock, and as a result of such ownership, such stockholders may influence the election of directors and other matters submitted to stockholders
2. 16The sale of our common stock to Lincoln Park Capital Fund LLC (“Lincoln Park”) may cause dilution to our other stockholders and the subsequent sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall
3. 17There may be future sales or other dilution of our equity, which may adversely affect the market price of our common stock
4. 18Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our common stock
5. 19If we fail to satisfy any of the Nasdaq continued listing requirements, Nasdaq may take steps to delist our common stock. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with Nasdaq continued listing requirements would be successful
6. 20Anti-takeover provisions of Delaware law and provisions in our charter and bylaws could make a third-party acquisition of us difficult

Risks Related to our Financial Position and Capital Requirements

1. 21We may acquire businesses, assets or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions
2. 22Our ability to utilize our net operating loss carryforwards and tax credit carryforwards may be subject to limitations

Risks Related to Regulatory Requirements

1. 23We are subject to extensive and costly government regulation
2. 24The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we may be unable to produce revenue and our business will be substantially harmed
3. 25We may never be able to obtain regulatory approval for any product candidates that we develop in the future. If our future product candidates are ultimately not approved for any reason, our business, prospects, results of operations and financial condition would be adversely affected
4. 26Disruptions at the FDA and other government agencies caused by funding shortages or other events or conditions outside of their control could negatively impact our business
5. 27If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
6. 28Healthcare legislative reform measures may have a material and adverse effect on our business, financial condition, results of operations, and prospects

Risks Relating to Our Intellectual Property

1. 29If the licensor of our in-licensed technology does not obtain patent term extension for future products that we or our strategic partners or collaborators may successfully develop, our business may be materially harmed
2. 30Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect future products and product candidates that we or our strategic partners or collaborators may develop
3. 31We may not be able to protect our intellectual property rights throughout the world
4. 32We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
5. 33We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property
6. 34We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
7. 35We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
8. 36If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our business may be adversely affected